Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

Feeding jejunostomy placement: Placement of feeding jejunostomy at staging laparoscopy

Feeding jejunostomy placement at esophagectomy: Placement of feeding jejunostomy at esophagectomy

Study summary

Participants were diagnosed with esophageal cancer needing chemo- or radiochemotherapy before the potentially curing surgery consisting of esophagectomy. At the time of diagnosis, in all participants, a laparoscopy to complete staging was performed. In some patients, a feeding jejunostomy tube (FJT) was placed at the time of staging laparoscopy; in others, the FJT was placed at the time of esophagectomy. A common risk factor for higher morbidity and mortality is sarcopenia, a condition associated with low skeletal muscle. This study aims to determine whether the timing of the FJT placement affects the progress of sarcopenia.

Eligibility

Primary outcome measure(s)

• Quantification of the effect of timing of FJT placement on sarcopenia in patients with advanced stages of esophageal cancer in curative cancer treatment. — For each patient the investigated period is under one year. It starts with the time of diagnosis until approximately 6 months after esophagectomy.
  This will be measured by the skeletal muscle index (SMI) at three points: the first SMI is measured at the time of diagnosis, the second preoperatively at re-staging after completion of neoadjuvant therapy, and the third measurement is six months postoperatively. We expect that regular enteral feed through FJT during neoadjuvant therapy leads to higher SMI or less progress of sarcopenia compared to FJT placement at esophagectomy.

Trial sites (1)

Other trials for the same condition